Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cloudbreak Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Cloudbreak Therapeutics

Cloudbreak Therapeutics

Cloudbreak Therapeutics: A biotech firm repurposing approved drugs to treat eye diseases, utilizing a capital-efficient model.

HQ
Irvine, CA, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Cloudbreak Therapeutics, founded with a mission to innovate ocular drug development, is a clinical-stage biotechnology company. The company repurposes approved systemic drugs for ocular delivery to treat various eye diseases. Utilizing a capital-efficient business model based on VIC and 505(b)(2) pathways, Cloudbreak aims to quickly advance drug candidates through Phase II clinical trials and out-license global rights for further development and commercialization. Their product pipeline includes treatments for conditions such as pterygium, myopia progression, MGD, pinguecula, and diabetic macular edema.

Notable figures affiliated with Cloudbreak Therapeutics include an experienced management team and a distinguished scientific advisory board. The company has achieved significant milestones, including advancing multiple drug candidates to proof-of-concept Phase II clinical trials. Cloudbreak's innovative approach has positioned it as a promising player in the biotechnology sector, potentially transforming the treatment landscape for ocular diseases and improving patient outcomes globally.

Cloudbreak Therapeutics - Similar Companies

OcuCure Therapeutics logo

OcuCure Therapeutics

EyeCyte logo

EyeCyte

eyecyte.com

Iview Therapeutics logo

Iview Therapeutics

Qlaris Bio logo

Qlaris Bio

qlaris.bio

TearClear logo

TearClear

tearclear.com

Visiox logo

Visiox

visioxpharma.com

Phanes Therapeutics logo

Phanes Therapeutics

phanesthera.com

Vian Therapeutics logo

Vian Therapeutics

viantx.com

Curie.Bio logo

Curie.Bio

curie.bio

Iacta Pharmaceuticals logo

Iacta Pharmaceuticals

Breye Therapeutics logo

Breye Therapeutics

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Ocular Science logo

Ocular Science

ocularscience.com

Clearside Biomedical logo

Clearside Biomedical

clearsidebio.com

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

Cloudbreak Therapeutics - Quick Facts

Who are Cloudbreak Therapeutics' competitors?

Companies similar to Cloudbreak Therapeutics include OcuCure Therapeutics, EyeCyte, Iview Therapeutics and Qlaris Bio.

When was Cloudbreak Therapeutics founded?

Cloudbreak Therapeutics was founded in 2015.

Where is Cloudbreak Therapeutics' headquarters located?

Cloudbreak Therapeutics' headquarters is located in Irvine, CA, US.

When was Cloudbreak Therapeutics' last funding round?

Cloudbreak Therapeutics' most recent funding round was for $130M (USD) in January 2022.

How much has Cloudbreak Therapeutics raised to-date?

As of Jan 1, 2022, Cloudbreak Therapeutics has raised a total of $171.2M (USD).

How many employees does Cloudbreak Therapeutics have?

Cloudbreak Therapeutics has 30 employees as of Feb 4, 2024.

Cloudbreak Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Development
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified